Landmark papers published in 2017 have advanced our understanding of the molecular
heterogeneity of urothelial cancer, provided insights into the genomic evolution of the …

Simple Summary The treatment of urothelial carcinoma is challenging. While known
therapies are effective, the results can be variable. Known treatment modalities include …

Objectives Immune checkpoint inhibitors (ICIs) are indicated for metastatic urothelial cancer
(mUC), but predictive and prognostic factors are lacking. We investigated clinical variables …

Urothelial malignancies, including carcinomas of the bladder, ureters, and renal pelvis
comprised∼ 8% of new cancer cases in the USA in 2016. In the metastatic setting, 15% of …

Background The therapeutic landscape for advanced urothelial carcinoma (mUC) has
changed significantly since studies establishing superiority of cisplatin as first-line therapy …

Urothelial carcinoma (UC) is the second most common malignancy of the genitourinary
system and the sixth most common cancer in the United States. The overall incidence of UC …

Urothelial carcinoma (UC) is a frequent cause of cancer-related deaths worldwide.
Metastatic UC has been historically associated with poor prognosis, with a median overall …

Platinum-based chemotherapy has long been the backbone of treatment for urothelial
carcinoma. Immune checkpoint inhibitors have revolutionized the treatment paradigm and …

Traditional cisplatin-based chemotherapy has long been the mainstay treatment for
advanced urothelial carcinoma (UC), but the emergence of immune checkpoint inhibitors …

Purpose The application of platinum-based chemotherapeutic agents is the traditional
treatment paradigm for advanced and metastatic urothelial carcinoma, which has changed …